This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakashima, T. Articles by Hara, M. Search for Related Content PubMed PubMed Citation Articles by Nakashima, T. Articles by Hara, M.

Tetrocarcin A Inhibits Mitochondrial Functions of Bcl-2 and Suppresses Its Anti-apoptotic Activity

Drug Discovery Research Laboratories, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Nagaizumi-cho, Suntou-gun, Shizuoka 411-8731 [T. N., M. H.]; and Department of Neuroanatomy, Biomedical Research Center, Osaka University Medical School, Osaka 565-0871 [M. M.], Japan

Bcl-2 is an integral, intracellular membrane protein that prevents cells from undergoing apoptosis in response to a variety of cell death signals. It negatively regulates the activation of Caspase-3, which functions as effector of mammalian cell death pathways. Overexpression of Bcl-2 inhibits the caspase activities and apoptosis. A microbial secondary metabolite, Tetrocarcin A (TC-A), was identified as an inhibitor of the anti-apoptotic function of Bcl-2. Apoptosis could be induced in cell lines that overexpressed Bcl-2 or Bcl-X_L when the cells were treated with anti-Fas antibody, tumor necrosis factor , staurosporine, or Bax, in addition to TC-A. TC-A showed selectivity against the pro-apoptotic Bcl-2 family members, in that cells overexpressing CrmA or dominant-negative FADD could not undergo apoptosis with TC-A treatment. In Bcl-2-overexpressing cell lines, TC-A inhibited mitochondrial functions regulated by Bcl-2, resulting in Fas-triggered mitochondrial transmembrane potential loss and cytochrome c release. Inhibition of the mitochondrial functions of Bcl-2 and, thereby, its anti-apoptotic effect could serve as useful pharmacological targets. Thus, TC-A should serve as an archetype for specific inhibitors of Bcl-2 functions.

This article has been cited by other articles:

				G. Kroemer, L. Galluzzi, and C. Brenner Mitochondrial Membrane Permeabilization in Cell Death Physiol Rev, January 1, 2007; 87(1): 99 - 163. [Abstract] [Full Text] [PDF]

				U. Fischer and K. Schulze-Osthoff New Approaches and Therapeutics Targeting Apoptosis in Disease Pharmacol. Rev., June 1, 2005; 57(2): 187 - 215. [Abstract] [Full Text] [PDF]

				C. L. Oliver, M. B. Miranda, S. Shangary, S. Land, S. Wang, and D. E. Johnson (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-XL-mediated apoptosis resistance Mol. Cancer Ther., January 1, 2005; 4(1): 23 - 31. [Abstract] [Full Text] [PDF]

				G. Z. Rassidakis, L. J. Medeiros, T. P. Vassilakopoulos, S. Viviani, V. Bonfante, G. Nadali, M. Herling, M. K. Angelopoulou, R. Giardini, M. Chilosi, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens Blood, December 1, 2002; 100(12): 3935 - 3941. [Abstract] [Full Text] [PDF]

				V. M. Dirsch, H. Stuppner, and A. M. Vollmar Helenalin Triggers a CD95 Death Receptor-independent Apoptosis That Is Not Affected by Overexpression of Bcl-xL or Bcl-2 Cancer Res., August 1, 2001; 61(15): 5817 - 5823. [Abstract] [Full Text] [PDF]